Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts

Burlington, Canada, Mon, 04/27/2020 - 10:27

Protects performance potential by vaccinating growing pigs against influenza A virus in swine, as early as one day of age.

Burlington, Canada, April 27, 2020 – Boehringer Ingelheim Animal Health Canada has introduced Ingelvac Provenza™, making it possible to vaccinate swine against multiple strains of the influenza A virus in swine (IAV-S) as young as one day of age.^1-5

Only Ingelvac Provenza™ uses innovative NS1 truncation technology, allowing this intranasal live attenuated influenza vaccine to generate strong, lasting immunity and provides a rapid response when the animal is exposed to wild type influenza.^{4, 6}

Influenza A virus in swine can have an extensive influence on the health of the pig population and subsequently can lead to major economic losses in pig production. A study has shown (linking historical diagnostic reports with closeout information to determine the production and economic impact) that uncomplicated IAV-S can lead to an estimated loss of more than $3.23 per pig⁷. In an additional study measuring the respiratory pathogen burden in growing pigs to estimate the impact of one or multiple diseases, when IAV-S was present with concurrent infections like with Porcine Reproductive and Respiratory Syndrome (PRRS) virus the losses could increase to $18 or more⁸ versus IAV-S alone⁷.

With these production losses at risk, Dr. Christa Goodell DVM, MS, PhD, Dipl ACVPM, with the Boehringer Ingelheim U.S. Swine Business, demonstrated that Ingelvac Provenza™ delivers measurable value in the respiratory disease complex. The pigs vaccinated with Ingelvac Provenza™ had significantly greater Average Daily Weight Gain (ADWG), and less variability, than non-vaccinated cohorts.⁹

Boehringer Ingelheim Canada (Ltd.)
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.ca or in our annual report: http://annualreport.boehringer-ingelheim.com.

References:

1. Alvarez J, Sarradell J, Kerkaert B, et al. Association of the presence of influenza A virus and porcine reproductive and respiratory syndrome virus in sow farms with post-weaning mortality. Prev Vet Med. 2015;121:240–245.
2. BIAH studies #2013200,2013232,and 2014001 published on http://productdata.aphis.usda.gov.
3. Genzow M, Goodell C, Kaiser T.J, Johnson W, Eichmeyer M. Live attenuated influenza virus vaccine reduces virus shedding of newborn piglets in the presence of maternal antibody. Influenza and Other Respiratory Viruses.2018;12(3): 353-359.
4. Vincent A.L, Ma W, Lager K.M, et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine. 2007;25:7999–8009.
5. Janke B.H. Influenza A virus infections in swine: pathogenesis and diagnosis.Vet Pathol.2014;51:410–426
6. Vincent A.L, Ma W, Lager K.M, Richt A.J, Janke B.H, Sandbulte M.R, Gauger P.C, Loving C.L, Webby R.J, García-Sastre A. Live Attenuated Influenza Vaccine Provides Superior Protection from Heterologous Infection in Pigs with Maternal Antibodies without Inducing Vaccine-Associated Enhanced Respiratory Disease.J Virol.2012 Oct; 86(19): 10597-10605.
7. Dykhuis Haden C, Painter T, Fangman T, Holtkamp D. Assessing production parameters and economic impact of swine influenza, PRRS and Mycoplasma hyopneumoniae on finishing pigs in a large production system. AASV 2012: 75-76.
8. Stika R, Holtkamp M.S, Goodell C, et al. Measuring the respiratory pathogen burden in growing pigs to estimate the impact of disease. Allen D. Leman Swine Conference; September 15–18, 2018; St. Paul,MN. Poster
9. Goodell C, Playter S, Fergen B, Plazola R. Benefits of live attenuated influenza vaccination in neonatal commercial pigs, observed after challenge with contemporary IAV-S at 10 and 15 weeks of age. AASV 2019: 128-131.